Home » Abstracts » Biomarkers & Drug discovery » Proteomic Profiling of Elite Athletes: Discovering Serum Biomarkers of Long-Term High-Intensity Exercise

Proteomic Profiling of Elite Athletes: Discovering Serum Biomarkers of Long-Term High-Intensity Exercise

Abstract #61 Posted on28 February 202529 April 2025 29 April 2025 9h59

Abstract

This investigation examines serum proteomic profiles of elite athletes, marathoners & weightlifters, age-sex matched controls, and cancer patients receiving cardiac fibrosis inducer doxorubicin. We aim to identify serum biomarkers for cardiovascular health and elucidate the impact of contrasting exercise modalities on serum.
Samples were processed with iST and analyzed via nLC-QTOF maXis II ETD. Raw data were analyzed with MaxQuant. Statistical analyses were performed using Perseus. Across all groups, 300 unique proteins were identified. Comparative analysis with 1% FDR and p-value threshold of 0.05 revealed 31 differentially expressed proteins in different groups.
Acute phase reactants are elevated in patients, and LRG1 and ORM2 increased in both weightlifters and patients. FN1 decreased significantly in weightlifters compared to rest, confirmed by western blot. In marathoners, GPLD1 and VWF are elevating, while LGALS3BP is decreasing. These findings suggest FN1 may serve as a potential serum biomarker for vascular degeneration. Exercise upregulates FN1 in slow-twitch muscle fibers but suppresses it in fast-twitch, suggesting FN1's potential to discriminate muscle fiber types.
This study provides insights into serum proteomic signatures of elite athletes and chemotherapy patients. Our findings may have implications for understanding cardiovascular health and guide future research on exercise-related health outcomes and potential biomarkers for cardiovascular risk assessment

Abstract N°

Review committee

Sélectionnez le(s) utilisateur(s) chargé(s) de la revue de cet abstract.

Communication type

Speaker abstract
Oral presentation
Flash communication
Poster

Communication status

Accepted
Rejected

Final abstract N°

Note globale

Abstract content *

Max 2000 characters. Line breaks are supported.

This investigation examines serum proteomic profiles of elite athletes, marathoners &amp; weightlifters, age-sex matched controls, and cancer patients receiving cardiac fibrosis inducer doxorubicin. We aim to identify serum biomarkers for cardiovascular health and elucidate the impact of contrasting exercise modalities on serum.
Samples were processed with iST and analyzed via nLC-QTOF maXis II ETD. Raw data were analyzed with MaxQuant. Statistical analyses were performed using Perseus. Across all groups, 300 unique proteins were identified. Comparative analysis with 1% FDR and p-value threshold of 0.05 revealed 31 differentially expressed proteins in different groups. 
Acute phase reactants are elevated in patients, and LRG1 and ORM2 increased in both weightlifters and patients. FN1 decreased significantly in weightlifters compared to rest, confirmed by western blot. In marathoners, GPLD1 and VWF are elevating, while LGALS3BP is decreasing. These findings suggest FN1 may serve as a potential serum biomarker for vascular degeneration. Exercise upregulates FN1 in slow-twitch muscle fibers but suppresses it in fast-twitch, suggesting FN1's potential to discriminate muscle fiber types.
This study provides insights into serum proteomic signatures of elite athletes and chemotherapy patients. Our findings may have implications for understanding cardiovascular health and guide future research on exercise-related health outcomes and potential biomarkers for cardiovascular risk assessment

Author(s) informations *

1	First name * Last name * email * Presenting author * At least and only one presenting author must be selected per abstract Presenting author Do you want this email to appear in the book of abstracts? If you refuse, only the administrators and the review commitee will have access to this email as part of the review process. YesNo Laboratory * Address * ZIP code * City * Country *
2	First name * Last name * email * Presenting author * At least and only one presenting author must be selected per abstract Presenting author Do you want this email to appear in the book of abstracts? If you refuse, only the administrators and the review commitee will have access to this email as part of the review process. YesNo Laboratory * Address * ZIP code * City * Country *
3	First name * Last name * email * Presenting author * At least and only one presenting author must be selected per abstract Presenting author Do you want this email to appear in the book of abstracts? If you refuse, only the administrators and the review commitee will have access to this email as part of the review process. YesNo Laboratory * Address * ZIP code * City * Country *
4	First name * Last name * email * Presenting author * At least and only one presenting author must be selected per abstract Presenting author Do you want this email to appear in the book of abstracts? If you refuse, only the administrators and the review commitee will have access to this email as part of the review process. YesNo Laboratory * Address * ZIP code * City * Country *
5	First name * Last name * email * Presenting author * At least and only one presenting author must be selected per abstract Presenting author Do you want this email to appear in the book of abstracts? If you refuse, only the administrators and the review commitee will have access to this email as part of the review process. YesNo Laboratory * Address * ZIP code * City * Country *
1	First name * Last name * email * Presenting author * At least and only one presenting author must be selected per abstract Presenting author Do you want this email to appear in the book of abstracts? If you refuse, only the administrators and the review commitee will have access to this email as part of the review process. YesNo Laboratory * Address * ZIP code * City * Country *

Add another author

Are you an ECR? *

<7 years after last degree

Are you a Junior PI? *

If you have started your own group less than 3 years ago and are not chosen by the scientific committee for a talk, you will have the opportunity to give a keynote during an ECR parallel session

Are you an invited speaker? *

Consent *

By submitting this form I agree
- that the administrators use my personal information for the abstract revision process.
- that my name, affiliation and abstract content may be publicly displayed.

Captcha